📣 WCN’26 Social Media Team Kickoff Meeting We’re delighted to welcome our new team members 🙌🏼 Meet the people behind the content: 🔗 theisn.org/wcn/media/so... #ISNWCN

🔬 Stay on top of the evidence At #ISNWCN, the HIT & LBCT sessions spotlight the clinical trials that matter most for patient care, from late-breaking results to ongoing studies. “As a community, this helps us stay on top of the evidence base,” says Adeera Levin. Read more: lite.spr.ly/6003OtWX

Meet the #ISNWCN Social Media Team! 🎉 A group of health pros bringing you live updates from WCN'26 in Yokohama, 🇯🇵, with scientific session coverage, quizzes, interviews, visual abstracts, workshops & more! Get ready for engaging content! lite.spr.ly/6008OsHw

#Dapagliflozin in CKD Patients with #Fabry Disease #VisualAbstract by Elba Medina https://www.kireports.org/article/S2468-0249(25)00760-0/fulltext

It's 2026!🎉 We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST. Join us on TWITTER (it will always be Twitter to us). Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down. www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025

Did we (meaning "you" of course, because you voted) get them right? Is there something missing or is the order wrong? #NephJC #TopTenStories2025 Come discuss with an international cadre of nephrologists & other interested parties on 1/6/26 at 9 pm EST on #Twitter

✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award 👇Here's a reminder of previous winners #Nephsky 📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form www.nephjc.com/news/2026/1/...

The future of nephrology

22/🎥Functional imaging studies have enhanced our understanding of physiology & pathology. 📸 However, most techniques are limited by variability in platforms, protocols, and image analysis. Standardization is crucial to unlock their full potential!🤳

“Nuestras cicatrices nos hacen saber que nuestro pasado fue real” Jane Austen

10/ Evaluating tubular function through dynamic physiological stress tests is essential for a comprehensive understanding of kidney function. e.g the furosemide stress test assesses renal tubular integrity.

5/ Read the executive summary and watch the meeting video for more information. 🔥🔥Start with the majors' key research questions🔥🔥

Congratulations to Leo Riella and team reporting physiology aspects from the first porcine kidney transplanted to a human. Happy to have contributed findings on pig renin and the renin-angiotensin system. @natcomms.nature.com @nu-nephrology.bsky.social @nufeinbergmed.bsky.social rdcu.be/eIyQt

Thanks to @asnpublications.bsky.social for highlighting our feature on a new syndrome of renal tubular alkalosis! www.kidneynews.org/view/journal... @nu-nephrology.bsky.social @nufeinbergmed.bsky.social

Do we continue to measure kidney function with tools from the last century? The workshop for Kidney Function Assessment of @NIDDKgov proposes a revolution: Go beyond Creatinine & eGFR! 💥Check out this blog & Skytorial !🧵👇 @kireports.bsky.social 👇👇👇👇👇👇 www.kireportscommunity.org/post/towards...

1/Hey #NephTwitter! Welcome to a 🆕 #Skytorial brought to you by @kireports.bsky.social @isnkidneycare.bsky.social Our author is @elbaonelida.bsky.social nephrologist at Hospital General de Mexico 🇲🇽 @hgm_nefrologia. Please also check out www.kireportscommunity.org educational #blogposts. FOLLOW US!

The LIBERATE-D VA by @sejalplakhani.bsky.social Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky www.nephjc.com/news/liberateva

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

Gracias! @dramiliflores.bsky.social #NephSky LIBERATE-D: El Resumen Visual — #NephJC www.nephjc.com/news/2025/12/14/liberate-d-el-resumen-visual

🆕 #NephJCshort by @brianrifkin.bsky.social RETREAT-FRAIL- pragmatic RCT: is less BP medication worse in octogenarians? www.nephjc.com/news/hyperte...

Kidney Tertiary #LymphoidTissues and Poor #Immunosuppressive Response in #IgANephropathy #IgAN #VisualAbstract by Elba Medina https://www.kireports.org/article/S2468-0249(25)00677-1/fulltext

#NephJCshort on BICAR-ICU2 #Medsky #Nephsky ✍️ By @nephroseeker.medsky.social 🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors www.nephjc.com/news/2025/10...

T3f: #NephJC Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA). Do you think either has the advantage?

T3d: #NephJC In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role. In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.

T3c: #NephJC The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.

T2c: #NephJC 1° Endpoint At week 36- 🗓️ 📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7% 🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%

T0h: #NephJC Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation. www.kidneynews.org/v...#NephJC

T0i: #NephJC Mechanistic lead-in came from the JANUS ph2 study (N=16): 👉 dose-dependent reductions in IgA, IgG, IgM, and Gd-IgA1 by week 24 👉maintained through week 72 👍 concurrent proteinuria improvement and preserved eGFR pubmed.ncbi.nlm.nih....#NephJC

T0j: #NephJC The ORIGIN phase 2b trial 👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi 💉 Weekly atacicept 150 mg (wk 36) ⬆️ 35% greater UPCR reduction vs placebo ⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m² pubmed.ncbi.nlm.nih....#NephJC

T0k: #NephJC The 96-week extension demonstrated durability: ⬇️proteinuria fell 52% ⬇️Gd-IgA1 dropped 66% ⬇️hematuria declined 75% ⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m² ⚠️Safety: mild injection-site reactions and transient infections pubmed.ncbi.nlm.nih....#NephJC

🥁 Drum rolls… The ORIGINal saga in IgAN unfolds. Interim chapter at 36 weeks, curtain rises, but the finale will still remain hidden. Moving on to RESULTS next #NephJC

T0d: #NephJC 🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate 📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope By @brendonneuen.bsky.social &Co pubmed.ncbi.nlm.nih....#NephJC

T0a: #NephJC Remember 2021, and the first glomerulonephritis @kdigo.org guidelines for IgAN? Only RASi and steroids were viable treatment options. However, it seems in 2025 we have so many other options, no?

🎨Beautiful visual abstract by @salinesolut.bsky.social

Tonite 11/18/25 on #Bluesky 9pm EST We are discussing ORIGIN3 and atacicept in IgAN. APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻) It's going to be Wicked good. 🧙‍♀️ #NephJC Summary by @notjustdialysis.bsky.social www.nephjc.com/news/atacicept-origin3-gtfb36

#Empagliflozin and #Ultrafiltration Volume in Patients Undergoing #PeritonealDialysis #VisualAbstract by Elba Medina https://www.kireports.org/article/S2468-0249(25)00624-2/fulltext

As nephrologists, we tend to focus on pathways, labs, and outcome curves. For years, IgAN meant familiar drugs and modest gains. Reading new guidelines through a patient’s story is a reminder of why it matters #nephjc Perspective by @jonathanpollack.bsky.social www.nephjc.com/news/2025/10...

IgA nephropathy: The immune twist behind the Kidney decline!! Join us today to learn more on the recent (And first ever disease specific) evidence based KDIGO IgA Nephropathy guidelines. There’s still time to review the highlights before the discussion. #NephJC

Great read on ways of measuring renal function. Shout out to @elbaonelida.bsky.social www.kireportscommunity.org/post/towards...

Last #NephJC short on individual data meta-analysis showing that although we love flozins for their extensive benefits we actually don’t completely understand how they work #Nephsky ✍️Meta by @willkidney.bsky.social & co 📝 Write up by @nephroseeker.medsky.social www.nephjc.com/news/2025/10...

Check out the Spanish VA. #NephSky Como siempre muchas gracias @dramiliflores.bsky.social www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual

Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR? www.nephjc.com/news/2025/10...

Up next! CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍 On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC pubmed.ncbi.nlm.nih.gov/40876553/ #Skytorial by @nephromommy-akshu.bsky.social Akshaya's signing off 👋

Chimerism might just be the 🔑 to immune tolerance and ending the need for immunosuppression 🚫💊after transplantation 🫘. Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC www.nephjc.com/news/chimera-tolerance-njqe334

It's that time of year again 🍂🍂🍂 The #NephJC Fall pledge drive. Plese give if you are able to support our decades long mission of #FOAMed for all. #NephSky #MedSky www.nephjc.com/news/2025/9/22/nephjc-fall-pledge-drive

1/10 Welcome to #TenPostNephJC Last #NephJC we discussed about AHA/ACC 2025 Hypertension guidelines: PREVENT, Detect, Treat Didn’t catch the pulse of this one? No worries we’ll help you pressure check the 2025 AHA Hypertension Guidelines. ❤ #AHA2025 www.ahajournals.org/doi/10.1161/...

GLP1ra in ADPKD? pubmed.ncbi.nlm.nih.gov/40815122/

Before we start, take a look at the guideline itself: www.ahajournals.org/... Does anyone see the authors? #nephjc

Check out the insightful VA that makes sense of the updates 🧠 #nephjc VA by @sejalplakhani.bsky.social